Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers

Zhifu Sun, Liang Wang, Bruce W. Eckloff, Bo Deng, Yi Wang, Jason A. Wampfler, Jinsung Jang, Eric D. Wieben, Jin Jen, Ming You, Ping Yang

Research output: Contribution to journalArticle

Abstract

Background: Novel and targetable mutations are needed for improved understanding and treatment of lung cancer in never-smokers. Methods. Twenty-seven lung adenocarcinomas from never-smokers were sequenced by both exome and mRNA-seq with respective normal tissues. Somatic mutations were detected and compared with pathway deregulation, tumor phenotypes and clinical outcomes. Results: Although somatic mutations in DNA or mRNA ranged from hundreds to thousands in each tumor, the overlap mutations between the two were only a few to a couple of hundreds. The number of somatic mutations from either DNA or mRNA was not significantly associated with clinical variables; however, the number of overlap mutations was associated with cancer subtype. These overlap mutants were preferentially expressed in mRNA with consistently higher allele frequency in mRNA than in DNA. Ten genes (EGFR, TP53, KRAS, RPS6KB2, ATXN2, DHX9, PTPN13, SP1, SPTAN1 and MYOF) had recurrent mutations and these mutations were highly correlated with pathway deregulation and patient survival. Conclusions: The recurrent mutations present in both DNA and RNA are likely the driver for tumor biology, pathway deregulation and clinical outcomes. The information may be used for patient stratification and therapeutic target development.

Original languageEnglish (US)
Article number32
JournalBMC Medical Genomics
Volume7
Issue number1
DOIs
StatePublished - Jun 4 2014
Externally publishedYes

Fingerprint

Critical Pathways
Mutation
Genes
Messenger RNA
DNA
Neoplasms
Exome
erbB-1 Genes
Adenocarcinoma of lung
p53 Genes
Gene Frequency
Lung Neoplasms
RNA
Phenotype
Survival

Keywords

  • Lung adenocarcinoma of never smoker
  • Pathway deregulation
  • Patient survival
  • Somatic mutations

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers. / Sun, Zhifu; Wang, Liang; Eckloff, Bruce W.; Deng, Bo; Wang, Yi; Wampfler, Jason A.; Jang, Jinsung; Wieben, Eric D.; Jen, Jin; You, Ming; Yang, Ping.

In: BMC Medical Genomics, Vol. 7, No. 1, 32, 04.06.2014.

Research output: Contribution to journalArticle

Sun, Z, Wang, L, Eckloff, BW, Deng, B, Wang, Y, Wampfler, JA, Jang, J, Wieben, ED, Jen, J, You, M & Yang, P 2014, 'Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers', BMC Medical Genomics, vol. 7, no. 1, 32. https://doi.org/10.1186/1755-8794-7-32
Sun, Zhifu ; Wang, Liang ; Eckloff, Bruce W. ; Deng, Bo ; Wang, Yi ; Wampfler, Jason A. ; Jang, Jinsung ; Wieben, Eric D. ; Jen, Jin ; You, Ming ; Yang, Ping. / Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers. In: BMC Medical Genomics. 2014 ; Vol. 7, No. 1.
@article{e63d5c39eae84bb9bf7504021eb8c737,
title = "Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers",
abstract = "Background: Novel and targetable mutations are needed for improved understanding and treatment of lung cancer in never-smokers. Methods. Twenty-seven lung adenocarcinomas from never-smokers were sequenced by both exome and mRNA-seq with respective normal tissues. Somatic mutations were detected and compared with pathway deregulation, tumor phenotypes and clinical outcomes. Results: Although somatic mutations in DNA or mRNA ranged from hundreds to thousands in each tumor, the overlap mutations between the two were only a few to a couple of hundreds. The number of somatic mutations from either DNA or mRNA was not significantly associated with clinical variables; however, the number of overlap mutations was associated with cancer subtype. These overlap mutants were preferentially expressed in mRNA with consistently higher allele frequency in mRNA than in DNA. Ten genes (EGFR, TP53, KRAS, RPS6KB2, ATXN2, DHX9, PTPN13, SP1, SPTAN1 and MYOF) had recurrent mutations and these mutations were highly correlated with pathway deregulation and patient survival. Conclusions: The recurrent mutations present in both DNA and RNA are likely the driver for tumor biology, pathway deregulation and clinical outcomes. The information may be used for patient stratification and therapeutic target development.",
keywords = "Lung adenocarcinoma of never smoker, Pathway deregulation, Patient survival, Somatic mutations",
author = "Zhifu Sun and Liang Wang and Eckloff, {Bruce W.} and Bo Deng and Yi Wang and Wampfler, {Jason A.} and Jinsung Jang and Wieben, {Eric D.} and Jin Jen and Ming You and Ping Yang",
year = "2014",
month = "6",
day = "4",
doi = "10.1186/1755-8794-7-32",
language = "English (US)",
volume = "7",
journal = "BMC Medical Genomics",
issn = "1755-8794",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers

AU - Sun, Zhifu

AU - Wang, Liang

AU - Eckloff, Bruce W.

AU - Deng, Bo

AU - Wang, Yi

AU - Wampfler, Jason A.

AU - Jang, Jinsung

AU - Wieben, Eric D.

AU - Jen, Jin

AU - You, Ming

AU - Yang, Ping

PY - 2014/6/4

Y1 - 2014/6/4

N2 - Background: Novel and targetable mutations are needed for improved understanding and treatment of lung cancer in never-smokers. Methods. Twenty-seven lung adenocarcinomas from never-smokers were sequenced by both exome and mRNA-seq with respective normal tissues. Somatic mutations were detected and compared with pathway deregulation, tumor phenotypes and clinical outcomes. Results: Although somatic mutations in DNA or mRNA ranged from hundreds to thousands in each tumor, the overlap mutations between the two were only a few to a couple of hundreds. The number of somatic mutations from either DNA or mRNA was not significantly associated with clinical variables; however, the number of overlap mutations was associated with cancer subtype. These overlap mutants were preferentially expressed in mRNA with consistently higher allele frequency in mRNA than in DNA. Ten genes (EGFR, TP53, KRAS, RPS6KB2, ATXN2, DHX9, PTPN13, SP1, SPTAN1 and MYOF) had recurrent mutations and these mutations were highly correlated with pathway deregulation and patient survival. Conclusions: The recurrent mutations present in both DNA and RNA are likely the driver for tumor biology, pathway deregulation and clinical outcomes. The information may be used for patient stratification and therapeutic target development.

AB - Background: Novel and targetable mutations are needed for improved understanding and treatment of lung cancer in never-smokers. Methods. Twenty-seven lung adenocarcinomas from never-smokers were sequenced by both exome and mRNA-seq with respective normal tissues. Somatic mutations were detected and compared with pathway deregulation, tumor phenotypes and clinical outcomes. Results: Although somatic mutations in DNA or mRNA ranged from hundreds to thousands in each tumor, the overlap mutations between the two were only a few to a couple of hundreds. The number of somatic mutations from either DNA or mRNA was not significantly associated with clinical variables; however, the number of overlap mutations was associated with cancer subtype. These overlap mutants were preferentially expressed in mRNA with consistently higher allele frequency in mRNA than in DNA. Ten genes (EGFR, TP53, KRAS, RPS6KB2, ATXN2, DHX9, PTPN13, SP1, SPTAN1 and MYOF) had recurrent mutations and these mutations were highly correlated with pathway deregulation and patient survival. Conclusions: The recurrent mutations present in both DNA and RNA are likely the driver for tumor biology, pathway deregulation and clinical outcomes. The information may be used for patient stratification and therapeutic target development.

KW - Lung adenocarcinoma of never smoker

KW - Pathway deregulation

KW - Patient survival

KW - Somatic mutations

UR - http://www.scopus.com/inward/record.url?scp=84902810152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902810152&partnerID=8YFLogxK

U2 - 10.1186/1755-8794-7-32

DO - 10.1186/1755-8794-7-32

M3 - Article

C2 - 24894543

AN - SCOPUS:84902810152

VL - 7

JO - BMC Medical Genomics

JF - BMC Medical Genomics

SN - 1755-8794

IS - 1

M1 - 32

ER -